News
CELUW
0.0079
+1.28%
0.0001
Weekly Report: what happened at CELU last week (0406-0410)?
Weekly Report · 21h ago
Weekly Report: what happened at CELU last week (0330-0403)?
Weekly Report · 04/06 10:08
Celularity Delays Annual 10-K Filing Amid Strains
TipRanks · 04/01 01:49
Celularity delays annual report filing, cites liquidity and accounting staffing constraints
Reuters · 03/31 21:14
Weekly Report: what happened at CELU last week (0323-0327)?
Weekly Report · 03/30 10:08
Weekly Report: what happened at CELU last week (0316-0320)?
Weekly Report · 03/23 10:04
Weekly Report: what happened at CELU last week (0309-0313)?
Weekly Report · 03/16 10:04
NexGel announces terms of agreement of license for products from Celularity
TipRanks · 03/12 12:55
NEXGEL Announces Consideration Terms Of Agreement To License And Acquire Portfolio Of Commercial-Stage Regenerative Biomaterial Products From Celularity; Consideration To Include $15M Upfront Cash Payment And Addl. $20M In Milestone Payments
Benzinga · 03/12 12:53
Nexgel to pay USD 15 million upfront to acquire Celularity regenerative biomaterials portfolio
Reuters · 03/12 12:45
NEXGEL INC - DEAL EXPECTED TO TRIPLE ANNUAL REVENUE TO $35 MLN AND MAKE COMPANY PROFITABLE UPON CLOSING
Reuters · 03/12 12:45
Celularity reiterates strategic commercialization partnership with NEXGEL
TipRanks · 03/12 12:35
NEXGEL Signs Agreement With Celularity To License And Acquire 6 Biomaterial Products; Stock Down
NASDAQ · 03/11 14:22
Celularity Licenses Biomaterials Portfolio to NexGel Partner
TipRanks · 03/10 13:35
NexGel sign agreement to license, acquire portfolio of products from Celularity
TipRanks · 03/10 12:51
Celularity secures strategic license deal worth up to $35M for biomaterials portfolio
Seeking Alpha · 03/10 12:45
NEXGEL INC - EXPECTS TO CLOSE $14.9 MLN IN ADDITIONAL FINANCING IN Q1 OR EARLY Q2 2026
Reuters · 03/10 12:45
Celularity secures $35M strategic license deal
TipRanks · 03/10 12:41
Celularity Signs $35M Agreements For Its Placental-Derived Biomaterials Portfolio
Benzinga · 03/10 12:32
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
Benzinga · 03/10 12:30
More
Webull provides a variety of real-time CELUW stock news. You can receive the latest news about Celularity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELUW
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It also develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance and Interfyl products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).